Match!

Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma

Published on Jun 1, 2020in Hepatology14.971
· DOI :10.1002/HEP.31089
Laura Stuart1
Estimated H-index: 1
(Newcastle University),
Beth Lambourne1
Estimated H-index: 1
(Newcastle upon Tyne Hospitals NHS Foundation Trust)
+ 4 AuthorsJessica K. Dyson15
Estimated H-index: 15
(Newcastle University)
Abstract
Programmed cell death protein 1 receptor (PD-1) is a cell surface protein involved in immune response regulation. Pembrolizumab is a monoclonal antibody against PD-1 and used to treat patients with stage IV and III melanoma.(1) Immune-related hepatotoxicity is reported in 2-10% of patients(2) with case reports of vanishing bile duct syndrome(3), subacute biliary injury and immune cholangitis.(4).
  • References (4)
  • Citations (1)
📖 Papers frequently viewed together
1 Citations
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References4
Newest
Source
#1Jacob Schachter (Sheba Medical Center)H-Index: 35
#2Antoni Ribas (UCLA: University of California, Los Angeles)H-Index: 100
Last. Caroline RobertH-Index: 83
view all 20 authors...
Summary Background Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis. Methods In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, ...
223 CitationsSource
#1Wenjun WangH-Index: 3
#2Puyi LieH-Index: 1
Last. JianxingHeH-Index: 21
view all 4 authors...
Aims: Although existing evidence from clinical trials has demonstrated manifestation of hepatic adverse events with the use of immune checkpoint inhibitors (ICPIs), overall risks have yet to be reported. Therefore, we assessed the risk of hepatotoxicity associated with inhibitors of the immune checkpoint Materials and methods: We examined data from the Pubmed, Medline and Google Scholar databases. We also examined original studies and review articles for crossreferences Eligible studies included...
30 CitationsSource
#1Derek G. Doherty (University of Cambridge)H-Index: 41
#2P.T. Donaldson (University of Cambridge)H-Index: 54
Last. Roger Williams (University of Cambridge)H-Index: 135
view all 11 authors...
Susceptibility to autoimmune hepatitis in white patients is associated with the human leukocyte antigen class II antigens DR3 and DR4. To analyze the molecular basis of these associations, we used oligonucleotide probes to determine the DRB, DQA and DQB hypervariable nucleotide sequences in 119 patients with autoimmune hepatitis and 177 matched controls. DRB3*0101, which encodes DR52a, predisposed patients most strongly to the disease. It was present in 58% of patients and 25% of controls (corre...
170 CitationsSource
Cited By1
Newest
#1Kazuyuki MizunoH-Index: 4
#1Kazuyuki Mizuno (Nagoya University)
Last. Kenji Yokota (Nagoya University)H-Index: 12
view all 23 authors...
BACKGROUND: Liver injury induced by immune checkpoint inhibitors (ICIs) is an immune-related adverse event (irAE) whose incidence has increased with the broader use of ICIs in clinical practice. However, the incidental risk factors of immune-related liver injury are unknown. We investigated the clinical characteristics of immune-related liver injury. METHODS: A total of 546 patients treated with ICIs for advanced malignancies between September 2014 and February 2019 were included retrospectively...
Source